Uppsala University Hospital

The Undiagnosed Hackathon was conceptualized and designed by H.C., M. Cederroth, A.N., and A.M.D.V. Biological samples and phenotype data were collected by various authors, processed and analyzed under the coordination of A.M.D.V. et al. All authors participated in data analysis and interpretation, with A.M.D.V. et al. drafting the manuscript. A.N., H.C., and M. Cederroth secured funding.

AlzeCure Pharma announces a live event on Oct 23 featuring Dr. Rolf Karlsten discussing ACD440, a novel non-opioid analgesic for chronic neuropathic pain. The event includes updates on ACD440's clinical phase II progress and Q&A with AlzeCure's CEO and CMO.

AlzeCure Pharma announces a live event on Oct 23 featuring Dr. Rolf Karlsten discussing ACD440, a non-opioid analgesic for chronic neuropathic pain. The event includes updates on ACD440's clinical phase II progress and Q&A sessions. The event is in English, free to attend, and accessible via Finwire.

Sana Biotechnology, with no Q2 2024 revenues but $251.6M in cash, reported better-than-expected EPS of ($0.21). Key R&D focuses include SC291/SC262 for hematological malignancies, modified pancreatic islet cell IST, and SC291 for autoimmune diseases. Data updates crucial for valuation, with potential stock upside of 411% and downside risk of 80%. Strong cash position offers flexibility and reduces near-term dilution risk.